Trade Report: Today, Piper Jaffray Cos. Analysts Give Alexion Pharmaceuticals Inc. (ALXN) a $176.00 Price Target

Today, Piper Jaffray Cos. Analysts Give Alexion Pharmaceuticals Inc. (ALXN) a $176.00 Price Target

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received a $176.00 target price from investment analysts at Piper Jaffray Cos. in a report released on Sunday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 48.11% from the stock’s current price.

Several other research analysts have also weighed in on ALXN. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Saturday, July 9th. Royal Bank Of Canada initiated coverage on shares of Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They set an “outperform” rating and a $188.00 target price for the company. SunTrust Banks Inc. lowered their target price on shares of Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating for the company in a research note on Wednesday, July 13th. Leerink Swann reissued a “buy” rating and set a $200.00 price target on shares of Alexion Pharmaceuticals in a research report on Sunday, July 17th. Finally, Jefferies Group reissued a “hold” rating and set a $140.00 price target (down previously from $159.00) on shares of Alexion Pharmaceuticals in a research report on Monday, July 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $173.36.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.08% on Friday, hitting $118.83. 472,545 shares of the stock were exchanged. The company’s 50 day moving average is $122.72 and its 200-day moving average is $129.05. Alexion Pharmaceuticals has a 52-week low of $110.56 and a 52-week high of $193.45. The stock has a market cap of $26647.39 billion, a PE ratio of 289.83 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.19. The company earned $799 million during the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. Alexion Pharmaceuticals’s revenue was up 19.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.16 earnings per share. Analysts predict that Alexion Pharmaceuticals will post $4.64 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP Carsten Thiel sold 1,000 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $125.94, for a total value of $125,940.00. Following the completion of the sale, the executive vice president now owns 40,579 shares in the company, valued at approximately $5,110,519.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leonard Bell sold 37,317 shares of Alexion Pharmaceuticals stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $140.38, for a total value of $5,238,560.46. Following the completion of the sale, the director now owns 440,936 shares of the company’s stock, valued at approximately $61,898,595.68. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ALXN. Beacon Capital Management purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth about $0. Investors Capital Advisory Services boosted its stake in shares of Alexion Pharmaceuticals by 0.7% in the second quarter. Investors Capital Advisory Services now owns 1,996 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 14 shares during the last quarter. Navellier & Associates Inc boosted its stake in shares of Alexion Pharmaceuticals by 0.5% in the second quarter. Navellier & Associates Inc now owns 3,477 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 17 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Alexion Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,090 shares of the biopharmaceutical company’s stock worth $869,000 after buying an additional 20 shares during the last quarter. Finally, Bremer Trust National Association boosted its stake in shares of Alexion Pharmaceuticals by 0.5% in the third quarter. Bremer Trust National Association now owns 5,478 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 26 shares during the last quarter. Institutional investors own 96.55% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Related posts

Leave a Comment